Delivery Order SPE2DB20D3103-SPE2DB26FL5A1
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $38,412.50 for GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product, with a ceiling value of $10,975.00. Issued on September 9, 2025, with an ultimate completion date of September 10, 2025, this firm fixed-price delivery order represents a competitive award with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $9,684.64 delivery order to AmerisourceBergen Drug Corp for GONAL-F RFF REDI-JECT 900 UNIT 1.44ML, a pharmaceutical product, with an ultimate completion date of October 31, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of GONAL-F RFF Redi-Ject 900 Unit 1.44ML pharmaceutical product with a ceiling value of $33,834.30. This firm fixed-price delivery order, with an ultimate completion date of July 29, 2025, will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The contract was competitively awarded without set-aside provisions, reflecting...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,195.04 to AmerisourceBergen Drug Corp for GONAL-F RFF Redi-Ject 300 Unit 0.48ML pharmaceutical product. This competitive, non-set-aside contract was awarded on November 10, 2025, with an ultimate completion date of November 12, 2025. The delivery order operates under a firm fixed price structure and represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- AmerisourceBergen Drug Corp was awarded a delivery order contract valued at $16,462.50 by the Defense Logistics Agency (DLA) Medical Supply Chain on September 8, 2025, for the supply of GONAL-F RFF REDI-JECT 900 Unit 1.44ML, a pharmaceutical product. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award selection. Performance will be executed from the company's corporate office location in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a $2,743.75 firm fixed price delivery order to AmerisourceBergen Drug Corp for GONAL-F RFF REDI-JECT 900 Unit 1.44ML, a specialty pharmaceutical product. The contract was awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, and will be performed in Conshohocken, Pennsylvania. This delivery order is a non-set-aside, competitively awarded transaction and represents a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency (DLA) awarded a $30,760.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp for GONAL-F RFF REDI-JECT 900 UNIT 1.44ML, a pharmaceutical product used in fertility treatment. This non-set-aside award, issued on July 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $4,146.49 to AmerisourceBergen Drug Corp for GONAL-F RFF REDI-JECT 900 UNIT 1.44ML, a pharmaceutical product. This firm fixed price delivery order, issued on July 31, 2025, with completion targeted for August 1, 2025, represents a child contract under AmerisourceBergen's larger federal contract portfolio. The award utilized no set-aside designation, indicating it was competitively awarded through standard procurement procedures. The...
- On July 22, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $40,816.93 to AmerisourceBergen Drug Corp for GONAL-F RFF REDI-JECT 900 UNIT 1.44ML pharmaceutical products. This firm fixed-price, non-set-aside delivery order is scheduled for completion by July 23, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL5A1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,459.06 to AmerisourceBergen Drug Corp for GONAL-F RFF Redi-Ject 900 Unit 1.44ML, a pharmaceutical product. This firm fixed price delivery order was awarded on November 4, 2025, with an ultimate completion date of November 5, 2025, and will be performed in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal procurement standards in open competition. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. The parent IDC functions as a global pharmaceutical support vehicle enabling the company to supply brand-name and generic medications, vaccines, specialty pharmaceuticals, and medical devices to multiple federal healthcare customers, including the Defense Health Agency and U.S. Coast Guard.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.5k | 11/4/25 |